Sector News

Bayer cuts loose diabetes care division for 1.02bn euros

June 10, 2015
Life sciences
Bayer is shedding its diabetes care division via a deal with long-term partner Panasonic Healthcare Holdings worth 1.02 billion euros.
 
The sale includes blood glucose monitoring systems, including the popular Contour portfolio of testers and strips, as well as lancing devices for patients with diabetes, which helped the unit bring in sales of 909 million euros last year.
 
The move seems a good fit for Panasonic. “For more than 20 years, our companies have shared complementary goals. We anticipate that this partnership will take our two great businesses to new heights,” said Kenji Yamane, President of Panasonic Healthcare Holdings, which is owned by investment group KKR (80%) and Panasonic Corp (20%). 
 
For Bayer, the transaction comes under its current strategy of honing its focus on life-sciences, as per which it also plans to de-merge and float on the stock market its MaterialScience unit by mid-2016.
 
The deal with Panasonic, which remains subject to customary conditions, including relevant antitrust clearance, is expected to close in the first quarter of next year.
 
By Selina McKee
 

comments closed

Related News

November 28, 2021

Founder-led biotech is making space for ideas—and diverse leaders—where it didn’t exist before

Life sciences

Decades ago, the founder-led biotech was rare and considered the tougher path to follow. Now there is a trend of founder-led biotechs that have risen in prominence in recent years, going from startup to well known with lightning speed. Scientists-turned C-suite occupants know their technology inside out. They’ve got credibility both at the bench working with their research teams and in the boardrooms selling their future products.

November 28, 2021

Pfizer to become $100B behemoth next year thanks to COVID-19 drug and vaccine: analyst

Life sciences

Pfizer’s revenue could reach $101.3 billion in 2022, with major contributions coming from the company’s BioNTech-partnered COVID vaccine and an antiviral therapeutic that has shown stellar clinical data, SVB Leerink analyst Geoffrey Porges projected in a Monday note to clients.

November 28, 2021

GlaxoSmithKline takes aim at sick pay access inequities with microgrant program and new campaign

Life sciences

In a survey commissioned by GlaxoSmithKline’s consumer health division of 2,000 working people in the U.S., almost 70% admitted to clocking in while sick, often because they couldn’t afford to lose a day’s pay. Black and Latina women were 10% more likely than white women to shun taking sick time for fear of fallout from their boss, according to the company’s 2021 Temperature Check Report.

Send this to a friend